Eli Lilly Raises 2013 Guidance After Q2 Sales Rise

July 24 (Bloomberg) -- Eli Lilly & Co., the maker of the antidepressant Cymbalta and diabetes treatment Humalog, raised its full-year guidance after second-quarter sales grew faster than expected and cost-cutting programs took effect. Olivia Sterns reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)

M&A Challenged by Political Volatility, Uncertainty
46:26 - Kurt Simon, vice chairman of M&A at JPMorgan, discusses how the 2016 presidential election is impacting the M&A market. He speaks on "Bloomberg Markets." (Source: Bloomberg)
  • An Inside Look at the $4.83 Billion Verizon-Yahoo Deal
  • Investors Go as Nintendo Captures Few Pokemon Profits
  • Triggering Article 50: When Will Brexit Talks Begin?